Down-regulation of phospho-non-receptor Src tyrosine kinases contributes to growth inhibition of cervical cancer cells

Medical Oncology

Volumn 28, Issue 4, 2011, Pages 1495-1506

  Kong, Lu ^a   Deng, Zhihong ^a   Zhao, Yanzhong ^b   Wang, Yamei ^a   Sarkar, Fazlul H ^c   Zhang, Yuxiang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer chemoprevention; Cell cycle; Cervical cancer; Non receptor Src tyrosine kinases

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CISPLATIN; CYCLIN A1; CYCLIN B; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; PHOSPHO SRC Y416; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL POPULATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; UPREGULATION; UTERINE CERVIX CANCER;

ADULT; AGED; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SRC-FAMILY KINASES; TRANSFECTION; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84655175113     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9583-3     Document Type: Article

References (27)

1. Initiative for vaccine research (IVR): human papillomavirus. World Health Organization Web site 2006.
2. "FDA Approves First Drug Treatment for Late-Stage Cervical Cancer", U.S. Food and Drug Administration (2006-06-15).
3. T Agorastos 2005 Detection and typing of human papillomavirus DNA in uterine cervices with coexistent grade I and grade III intraepithelial neoplasia: biologic progression or independent lesions? Eur J Obstet Gynecol Reprod Biol 121 1 99 103
4. Gottlieb N. A Primer on HPV. NCI benchmarks (2002-4-24). http://benchmarks.cancer.gov/2002/04/a-primer-on-hpv/.
5. G Manning DB Whyte R Martinez T Hunter S Sudarsanam 2002 The protein kinase complement of the human genome Science 298 1912 1934
6. RJ Roskoski 2004 The ErbB/HER receptor protein-tyrosine kinases and cancer Biochem Biophys Res Commun 319 1 11
7. AY Tsygankov SK Shore 2004 Src: regulation, role in human carcinogenesis and pharmacological inhibitors Curr Pharm Des 10 1745 1756
8. JB Bolen 1993 Non receptor tyrosine protein kinases Oncogene 8 2025 2031
9. AY Tsygankov JB Bolen 1993 The Src family of tyrosine protein kinases in hemopoietic signal transduction Stem Cells 11 371 380
10. S Hiscox L Morgan TP Green RI Nicholson 2006 Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer Endocr Relat Cancer 13 53 59
11. RK Nam 2005 The use of genetic markers to determine risk for prostate cancer at prostate biopsy Clin Cancer Res 11 8391 8397
12. JG Trevino 2006 Inhibition of Src expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model Am J Pathol 168 962 972
13. FM Johnson B Saigal M Talpaz NJ Donato 2005 Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells Clin Cancer Res 11 6924 6932
14. S Schenone F Manetti M Botta 2007 Synthetic Src-kinase domain inhibitors and their structural requirements Anti-Cancer Agents Med Chem 7 660 680
15. JH Hanke 1996 Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation J Biol Chem 271 2 695 701
16. Y Zhang 2006 Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-{kappa} B in pancreatic cancer Cancer Res 66 1025 1032
17. Z Wang Y Zhang S Banerjee Y Li FH Sarkar 2006 Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells Int J Cancer 118 1930 1936
18. T Hongo Y Fujii Y Igarashi 1990 An in vitro chemosensitivity test for the screening of anti-cancer drugs in childhood leukemia Cancer 65 1263 1271
19. WJ Durkin VK Ghanta RN Hiramoto 1983
20. LM Green JL Reade CF Ware 1984 Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines J Immunol Methods 70 257 268
21. PL Kornblith PE Szypko 1978 Variations in response of human brain tumors to BCNU in vitro J Neurosurg 48 580 586
22. FX Sun 2003 Efficacy of camptothecin analog DX-8951f (exatecan mesylate) on human pancreatic cancer in an Orthotopic metastatic model Cancer Res 63 80 85
23. K Neet T Hunter 1996 Vertebrate non-receptor protein-tyrosine kinase families Genes Cells 1 147 169
24. O Aprelikova Y Xiong ET Liu 1995 Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase J Biol Chem 270 18195 18197
25. J Bartek J Bartkova J Lukas 1997 The retinoblastoma protein pathway in cell cycle control and cancer Exp Cell Res 237 1 6
26. J Pines 1999 Four-dimensional control of the cell cycle Nat Cell Biol 1 E73 E79
27. CJ Sherr 1993 Mammalian G1 cyclins Cell 73 1059 1065